

Global Artificial Pancreas Devices Systems Market Size Study, by Device Type (Threshold Suspend Device Systems, Control-to-Range Systems, Control-to-Target Systems), by End User (Hospitals, Clinics, Homecare), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G773CEFF9AB6EN.html>

Date: February 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G773CEFF9AB6EN

Abstracts

Global Artificial Pancreas Devices Systems Market is valued at approximately USD 289.9 Million in 2023 and is anticipated to grow with a healthy growth rate of 18.9% over the forecast period 2024-2032. Artificial pancreas device systems, often referred to as closed-loop insulin delivery systems, represent a transformative advancement in diabetes management. By seamlessly integrating continuous glucose monitors (CGMs), insulin pumps, and algorithm-driven automation, these devices dynamically adjust insulin delivery, mimicking the glucose-regulating functions of a healthy pancreas. This automation significantly reduces the burden of manual interventions and improves glycemic control, offering enhanced quality of life for individuals with type 1 diabetes.

The market is experiencing a surge in demand due to the escalating prevalence of diabetes worldwide, coupled with rapid technological advancements in wearable devices and predictive algorithms. For instance, in May 2024, the FDA approved the CamAPS FX system for use in pregnancy, highlighting the growing adoption of personalized and context-specific diabetes management solutions. Additionally, the integration of mobile applications and wearable technology is redefining patient engagement, enabling real-time monitoring and seamless remote connectivity, thereby fostering market growth.

While the high costs associated with these devices and concerns regarding data privacy pose challenges, increasing healthcare investments and favorable reimbursement policies are expected to mitigate these barriers. The continued focus on expanding

access to advanced diabetes management solutions in emerging economies further underscores the market's potential for robust growth.

North America dominates the global market landscape, attributed to its well-established healthcare infrastructure, significant R&D investments, and the presence of major industry players. However, the Asia-Pacific region is anticipated to exhibit the fastest growth during the forecast period, driven by rising healthcare expenditure, large diabetic populations, and increasing awareness of digital health solutions.

Major market players included in this report are:

Medtronic Plc

Tandem Diabetes Care, Inc.

Beta Bionics

Bigfoot Biomedical, Inc.

Insulet Corporation

Diabeloop SA

Johnson & Johnson

Pancreum, Inc.

TypeZero Technologies, LLC

Roche Diabetes Care

Abbott Laboratories

Dexcom, Inc.

Animas Corporation

Inreda Diabetic

EoFlow Co., Ltd.

The detailed segments and sub-segments of the market are explained below:

By Device Type:

Threshold Suspend Device Systems

Control-to-Range (CTR) Systems

Control-to-Target (CTT) Systems

By End User:

Hospitals

Clinics

Homecare

By Region:

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

South Korea

Australia

Rest of Asia-Pacific

LAMEA (Latin America, Middle East & Africa)

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Years considered for the study are as follows:

Historical Year: 2022

Base Year: 2023

Forecast Period: 2024-2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional-level analysis for each market segment.

Detailed analysis of the geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations for future market approaches.

Demand-side and supply-side analysis of the market.

Contents

CHAPTER 1. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET EXECUTIVE SUMMARY

- 1.1. Global Artificial Pancreas Devices Systems Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Device Type
 - 1.3.2. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendations & Conclusion

CHAPTER 2. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.4. Demand Side Analysis
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study

CHAPTER 3. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET DYNAMICS

- 3.1. Market Drivers
 - 3.1.1. Rising Prevalence of Diabetes
 - 3.1.2. Advancements in CGM and Insulin Delivery Technologies
 - 3.1.3. Increasing Awareness of Diabetes Management
- 3.2. Market Challenges
 - 3.2.1. High Costs of Devices
 - 3.2.2. Cybersecurity and Data Privacy Concerns
- 3.3. Market Opportunities
 - 3.3.1. Expansion in Emerging Markets

3.3.2. Integration of AI and Mobile Technologies

CHAPTER 4. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Analysis

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Emerging Trends

4.5. Analyst Recommendations

CHAPTER 5. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET SIZE & FORECAST BY DEVICE TYPE

5.1. Segment Dashboard

5.2. Revenue Trends

- 5.2.1. Threshold Suspend Device Systems
- 5.2.2. Control-to-Range (CTR) Systems
- 5.2.3. Control-to-Target (CTT) Systems

CHAPTER 6. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET SIZE & FORECAST BY END USER

6.1. Segment Dashboard

6.2. Revenue Trends

- 6.2.1. Hospitals
- 6.2.2. Clinics
- 6.2.3. Homecare

CHAPTER 7. GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET SIZE & FORECAST BY REGION

7.1. North America

7.1.1. U.S.

7.1.2. Canada

7.1.3. Mexico

7.2. Europe

7.2.1. Germany

7.2.2. UK

7.2.3. France

7.2.4. Italy

7.2.5. Spain

7.2.6. Rest of Europe

7.3. Asia-Pacific

7.3.1. Japan

7.3.2. China

7.3.3. Australia

7.3.4. India

7.3.5. South Korea

7.3.6. Rest of Asia-Pacific

7.4. LAMEA (Latin America, Middle East & Africa)

7.4.1. Brazil

7.4.2. Saudi Arabia

7.4.3. South Africa

7.4.4. Rest of LAMEA

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Key Company SWOT Analysis

8.1.1. Medtronic Plc

8.1.2. Tandem Diabetes Care, Inc.

8.1.3. Beta Bionics

8.2. Top Market Strategies

8.3. Company Profiles

CHAPTER 9. RESEARCH PROCESS

- 9.1. Research Methodology
- 9.2. Data Collection and Validation
- 9.3. Primary Research Overview
- 9.4. Secondary Research Overview
- 9.5. Market Estimation Techniques
- 9.6. Data Triangulation
- 9.7. Data Sources and References
- 9.8. Research Limitations

I would like to order

Product name: Global Artificial Pancreas Devices Systems Market Size Study, by Device Type (Threshold Suspend Device Systems, Control-to-Range Systems, Control-to-Target Systems), by End User (Hospitals, Clinics, Homecare), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G773CEFF9AB6EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G773CEFF9AB6EN.html>